DMPHF OTC
Dermapharm Holding SE
1W: +0.0%
1M: +0.0%
3M: -10.0%
YTD: +20.6%
1Y: +20.6%
3Y: +17.4%
$47.69
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$1.2B
+2.6% ▲
5Y CAGR: +11.0%
Gross Profit
$767M
+8.9% ▲
5Y CAGR: +14.9%
Operating Income
$217M
+18.6% ▲
5Y CAGR: +12.7%
Net Income
$114M
+82.4% ▲
5Y CAGR: +8.1%
EPS (Diluted)
$2.11
+81.9% ▲
5Y CAGR: +8.1%
EBITDA
$321M
+22.1% ▲
5Y CAGR: +13.8%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $794M | $943M | $1.0B | $1.2B | $1.2B |
| YoY Growth | +13.3% | +18.8% | +8.7% | +12.3% | +2.6% |
| Cost of Revenue | $330M | $322M | $364M | $447M | $414M |
| Gross Profit | $463M | $621M | $661M | $704M | $767M |
| Gross Margin | 58.4% | 65.8% | 64.5% | 61.2% | 65.0% |
| R&D Expenses | $13M | $14M | $13M | $20M | $12M |
| SG&A Expenses | $67M | $66M | $67M | $95M | $88M |
| Operating Expenses | $318M | $334M | $419M | $521M | $550M |
| Operating Income | $137M | $298M | $244M | $183M | $217M |
| Operating Margin | 17.2% | 31.7% | 23.8% | 15.9% | 18.4% |
| Interest Expense | $9M | $9M | $15M | $55M | $58M |
| Income Before Tax | $125M | $293M | $216M | $106M | $172M |
| Tax Expense | $39M | $84M | $84M | $45M | $60M |
| Net Income | $86M | $210M | $134M | $62M | $114M |
| Net Margin | 10.8% | 22.2% | 13.1% | 5.4% | 9.6% |
| EPS (Diluted) | $1.59 | $3.89 | $2.49 | $1.16 | $2.11 |
| EBITDA | $182M | $357M | $324M | $263M | $321M |
| Shares Outstanding | 54M | 54M | 54M | 54M | 54M |